The Effectiveness of CBD and CBN in the Treatment of Facial Pain and Headache of Muscular Origin
| Trial ID | NCT05961501 |
| Status | Enrolling By Invitation |
| Condition | Myalgia |
| Intervention | An aqueous solution containing CBD and CBN |
Facial pain and headaches of muscular origin affect millions but lack standardized treatment protocols. This trial addresses a critical gap by evaluating specific cannabinoid combinations using objective electromyographic measurements rather than subjective pain scales alone.
This randomized, double-blind, placebo-controlled trial enrolls 42 adults with chronic (>3 months) facial pain and headache of muscular origin. Participants receive either an aqueous CBD/CBN solution or placebo for 60 days, with outcomes measured via electromyography, pressure pain threshold testing, and clinical examination at baseline, day 20, 40, and 60. The trial is currently enrolling by invitation and represents one of the first controlled studies examining this specific cannabinoid combination for myofascial pain.
“If positive, this trial could provide the evidence base I need to confidently recommend specific CBD/CBN formulations for patients with chronic facial myalgia. The objective EMG endpoints are particularly valuable for establishing clinical credibility.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is the CBD and CBN facial pain trial testing?
The trial is testing an aqueous solution containing CBD and CBN for chronic facial pain and headache of muscular origin. It is randomized, double-blind, and placebo-controlled: participants receive either the CBD/CBN solution or a placebo for 60 days. It is registered as NCT05961501, with myalgia listed as the condition.
Who is taking part in the CBD and CBN facial pain trial?
The trial enrolls 42 adults whose facial pain and headache of muscular origin has lasted more than three months. Enrollment is by invitation rather than open recruitment. The trial is described as one of the first controlled studies examining this specific cannabinoid combination for myofascial pain.
Outcomes are measured with electromyography, which records muscle activity, along with pressure pain threshold testing and clinical examination. These assessments take place at baseline and on days 20, 40, and 60. The trial relies on objective electromyographic measurements rather than subjective pain scales alone.
Are results from this CBD and CBN trial available yet?
Not yet. The trial is currently enrolling by invitation, so it is still under way and no findings are reported. Whether the CBD and CBN solution works better than placebo for facial pain and headache of muscular origin will only be known once the 60-day treatment results are analyzed.
